Table 1 Comparison of cardiology evaluation and cardiovascular imaging modalities in patients before/during treatment versus during survivorship care, by provider report. Patients were more likely to be evaluated by a cardiologist post-treatment or during survivorship care than prior/during cancer treatment. There was an increase in use of Cardiac MR imaging as part of survivorship care

Evaluation by a Cardiologist

8 (12%)

28 (43%)

< 0.01

Electrocardiogram

48 (75%)

43 (66%)

0.27

Extended arrhythmia monitoring

2 (3%)

7 (11%)

0.16

Echocardiogram, standard^a

37 (58%)

36 (55%)

0.77

Echocardiogram, advanced^b

32 (50%)

35 (54%)

0.66

Cardiac magnetic resonance imaging

2 (3%)

11 (17%)

< 0.01

Radionuclide imaging (e.g. MUGA)

0 (0%)

2 (3%)

0.50

Serum biomarkers

5 (8%)

n/a

–

Cardiopulmonary exercise testing

n/a

5 (8%)

–

None

0 (0%)

0 (0%)

1.00

Other/Unknown/not applicable

9 (14%)

8 (12%)

0.76